Hematologic and malignant disorders

1. High-Yield Summary

• Hematologic and malignant disorders of bone (primarily multiple myeloma, primary lymphoma of bone, leukemia, and solitary plasmacytoma) are marrow-based malignancies in which structural skeletal destruction is driven by uncoupled osteoclastic resorption rather than direct mechanical tumor erosion.
• Multiple myeloma diagnosis is governed by the updated International Myeloma Working Group (IMWG) SLiM-CRAB criteria: clonal marrow plasma cells >=10% or biopsy-proven plasmacytoma combined with end-organ damage (hypercalcemia, renal insufficiency, anemia, lytic bone lesions) or validated biomarkers (>=60% plasma cells, free light chain ratio >=100, >1 focal MRI lesion >5 mm).
• Impending pathologic fractures of long bones are risk-stratified using the validated Mirels scoring system: lesions with a score >=9 mandate prophylactic internal fixation prior to radiotherapy or systemic therapy, while scores <=7 can be safely treated nonoperatively.
• Surgical stabilization in hematologic malignancies requires full-length, load-sharing implants (typically intramedullary nails spanning the entire bone or locked plates augmented with polymethylmethacrylate [PMMA] cement), as biologic union cannot be expected in irradiated, tumor-infiltrated bone.
• Vertebral body compression fractures without spinal canal compromise or neurological deficit respond rapidly to percutaneous balloon kyphoplasty, restoring sagittal alignment, stabilizing painful micro-instability, and providing immediate pain relief.

2. Anatomy

The anatomic distribution of hematologic malignancies directly parallels the physiological persistence of active hematopoiesis and red marrow in adults. Red marrow is concentrated in the axial skeleton (vertebral column, pelvis, ribs, sternum, skull) and the proximal appendicular skeleton (proximal femoral and humeral metadiaphyses), establishing these regions as the primary sites of skeletal destruction, pathologic fractures, and surgical intervention.

Surgical Intervals and Internervous Planes

• Femoral Fixation and Reconstruction: Trochanteric entry intramedullary nailing utilizes the internervous interval between the gluteus medius (superior gluteal nerve) and the piriformis/tensor fasciae latae. For proximal femoral replacement or open curettage, the direct lateral (Hardinge) or anterolateral (Watson-Jones) approach exploits the plane between the tensor fasciae latae (superior gluteal nerve) and the rectus femoris (femoral nerve).
• Humeral Diaphyseal and Proximal Exposure: The anterior deltopectoral approach is strictly internervous between the deltoid (axillary nerve) and the pectoralis major (lateral and medial pectoral nerves). Distally in the humeral shaft, the anterolateral approach utilizes the plane between the brachialis (dual innervation: medial aspect by musculocutaneous nerve, lateral aspect by radial nerve) and the biceps brachii (musculocutaneous nerve).
• Spinal Decompression and Vertebroplasty Corridors: Percutaneous balloon kyphoplasty and transpedicular decompression traverse the osseous pedicle corridor. The safe zone is bounded medially by the dural sac, superiorly by the exiting nerve root in the neural foramen, and laterally by the segmental radicular vessels.

Neurovascular Danger Zones and Critical Landmarks

• Proximal Femur: The femoral neurovascular bundle lies immediately anterior to the hip joint capsule and psoas tendon. Posteriorly, the sciatic nerve exits the greater sciatic notch beneath the piriformis muscle, running directly posterior to the acetabulum and femoral neck. The calcar femorale represents the critical biomechanical buttress resisting varus loading; its destruction by osteolytic myeloma markedly increases the risk of catastrophic catastrophic hardware cutout.
• Humeral Shaft: The radial nerve traverses the spiral groove on the posterior and lateral aspect of the humeral diaphysis, approximately 14 to 15 cm proximal to the lateral epicondyle and 20 to 21 cm distal to the acromial tip. The axillary nerve courses circumferentially around the humeral surgical neck within the quadrangular space, located 5 to 7 cm inferior to the lateral border of the acromion.
• Vertebral Column: The anterior vertebral body is intimately associated with the descending thoracic aorta, inferior vena cava, common iliac vessels, and segmental lumbar arteries. The posterior cortical wall of the vertebral body directly borders the anterior epidural space and thecal sac; disruption of this cortex creates a direct danger zone for cement extravasation during vertebral augmentation.

3. Pathogenesis

The pathophysiology of skeletal destruction in hematologic malignancies is fundamentally characterized by uncoupled bone remodeling. In multiple myeloma, clonal plasma cells proliferate within the medullary marrow and orchestrate an imbalance between osteoclast activation and osteoblast suppression:

• Osteoclast Hyperactivation: Myeloma cells and marrow stromal cells secrete Receptor Activator of Nuclear Factor-kappa B Ligand (RANKL), macrophage inflammatory protein-1alpha (MIP-1alpha), interleukin-3 (IL-3), and interleukin-6 (IL-6). Concurrently, levels of osteoprotegerin (OPG), the endogenous decoy receptor for RANKL, are markedly suppressed. This high RANKL:OPG ratio triggers massive osteoclastogenesis and accelerated bone resorption.
• Osteoblast Inhibition: Unlike metastatic solid carcinomas (such as prostate or breast cancer) that often elicit a reactive osteoblastic or sclerotic response, multiple myeloma completely shuts down bone formation. Malignant plasma cells produce Wnt signaling antagonists, including Dickkopf-1 (DKK1) and secreted Frizzled-related protein-2 (sFRP-2), which inhibit mesenchymal stem cell differentiation into mature osteoblasts. Consequently, osteolytic lesions in myeloma exhibit zero reactive sclerosis and show no spontaneous repair, creating classic “punched-out” defects.
• Biomechanical Degradation: Progressive endosteal scalloping and cortical thinning reduce the cross-sectional moment of inertia, dramatically lowering the bone’s torsional and bending strength. Under physiologic weight-bearing and axial loading, microdamage accumulates rapidly, culminating in impending or completed pathologic fractures.
• Primary Bone Lymphoma: Lymphoma of bone, typically diffuse large B-cell lymphoma (DLBCL), produces a permeative, small round blue cell infiltration through Haversian and Volkmann canals without immediately destroying cortical architecture. This permeative pattern explains why patients often present with massive soft tissue extension despite relatively preserved cortical bone on plain radiographs.

4. Natural History

Multiple myeloma accounts for approximately 1% of all malignancies and 10% to 15% of all hematologic cancers. In North America and Europe, the annual incidence is 6 to 7 cases per 100,000 persons, with a median age at presentation of 69 years. Men are affected more frequently than women (1.5:1 ratio), and the disease has an incidence twice as high in individuals of African ancestry compared to Caucasian populations.

If left untreated, hematologic bone disorders follow a devastating course marked by recurrent skeletal-related events (SREs). In natural history cohorts prior to effective systemic therapy, over 60% of multiple myeloma patients developed pathologic fractures, 10% suffered spinal cord or cauda equina compression, and severe hypercalcemic crises were frequent causes of emergency admission and early mortality. Progressive osteolysis leads to chronic intractable pain, immobility, muscle wasting, thromboembolic complications, and profound loss of functional independence.

Solitary plasmacytoma of bone occurs in approximately 5% of patients presenting with plasma cell neoplasms. Even following definitive local radiation therapy (40 to 50 Gy), 65% to 85% of patients with solitary osseous plasmacytomas eventually progress to systemic multiple myeloma within 3 to 10 years, necessitating lifelong surveillance. Primary bone lymphoma constitutes less than 5% of primary bone tumors and approximately 7% of extranodal lymphomas, presenting most commonly in adults aged 45 to 65 years. When managed with modern immunochemotherapy and consolidation radiotherapy, localized primary bone lymphoma achieves a favorable prognosis, with 5-year overall survival rates reaching 75% to 85%.

5. Clinical Presentation

History

• Mechanical Bone Pain: The cardinal presenting symptom (present in >70% of patients) is deep, aching, localized bone pain. Unlike mechanical degenerative arthritis, pain from hematologic bone lesions is characteristically worse with movement and weight-bearing, frequently persists at rest, and awakens the patient at night.
• Constitutional Manifestations: Unexplained fatigue, generalized weakness, and dyspnea on exertion reflect underlying normocytic normochromic anemia. Recurrent bacterial infections (particularly pneumonia and pyelonephritis) result from functional hypogammaglobulinemia. Unintended weight loss, fevers, and drenching night sweats (“B symptoms”) are classic in lymphoma.
• Hypercalcemia Features: Nausea, obstipation, polyuria, polydipsia, lethargy, confusion, and shortened QT interval on electrocardiography (“bones, stones, abdominal groans, and psychiatric overtones”).
• Neurological Red Flags: Progressive lower extremity weakness, sensory loss, band-like radicular trunk pain, or bowel/bladder sphincter dysfunction indicate acute spinal cord or cauda equina compression demanding immediate neurosurgical and orthopaedic intervention.

Physical Examination and Diagnostic Benchmarks

• Spinous Process Percussion: Direct, gentle percussion over the vertebral column identifies focal tenderness corresponding to acute vertebral body collapse or tumor extension [Sensitivity 82%, Specificity 68%].
• Axial Stressed Stance Test: Elicitation of sharp localized pain in the groin or thigh during assisted single-leg stance or gentle axial compression of the femur indicates structural compromise and high risk of impending pathologic fracture [Sensitivity 89%, Specificity 74%].
• Comprehensive Neurological Examination: Motor strength testing using the Medical Research Council (MRC) 0-5 scale, sensory dermatomal testing, deep tendon reflex appraisal, and screening for long-tract signs (positive Babinski response, ankle clonus, Hoffmann sign) to rule out myelopathy [Sensitivity 88%, Specificity 92%].
• Peripheral Lymphadenopathy and Visceromegaly: Systemic palpation of cervical, axillary, and inguinal lymph node basins and abdominal examination for splenomegaly help distinguish lymphoma or leukemia from isolated multiple myeloma.

6. Imaging and Diagnostic Studies

The diagnostic evaluation of suspected hematologic and malignant disorders of bone requires a multimodal imaging approach combined with definitive laboratory, marrow, and histological verification.

Radiographic Hierarchy

• Whole-Body Low-Dose CT (WBLD-CT): Modern guidelines from the International Myeloma Working Group (IMWG) establish WBLD-CT as the superior first-line imaging standard over conventional plain skeletal surveys. WBLD-CT identifies osteolytic lesions as small as 2 to 5 mm, accurately quantifies cortical destruction and trabecular loss, and detects impending fracture risks with a sensitivity of 85% to 90% (compared to only 50% to 60% for plain radiography).
• Conventional Plain Radiography: Full skeletal surveys (AP/lateral views of the skull, cervical/thoracic/lumbar spine, pelvis, humeri, and femora) show pathognomonic “punched-out” purely lytic lesions without reactive osteosclerosis, diffuse osteopenia, endosteal scalloping, and vertebral wedge compressions with preserved intervertebral disc heights. However, plain films require 30% to 50% trabecular bone loss before lesions become visible.
• Magnetic Resonance Imaging (MRI): Whole-body or targeted MRI is the gold standard modality for evaluating the spine and pelvis. MRI evaluates the pattern of marrow infiltration (focal vs diffuse), assesses epidural soft-tissue extension and neural element compression, and differentiates malignant compression fractures (diffuse marrow replacement, posterior cortex convex bulging, pedicle involvement) from benign osteoporotic fractures. The detection of >1 focal lesion (>5 mm) on MRI fulfills the IMWG biomarker criteria for active multiple myeloma.
• 18F-FDG PET-CT: Highly sensitive for detecting active metabolic disease, identifying extramedullary plasmacytomas, guiding percutaneous biopsy to the most metabolically active site, and monitoring therapeutic response or minimal residual disease (MRD).

Laboratory and Histopathologic Evaluation

• Serum and Urine Protein Electrophoresis (SPEP / UPEP): Identifies monoclonal immunoglobulin spikes (M-protein: IgG in ~55%, IgA in ~20%, light chain only in ~15%). Immunofixation confirms heavy- and light-chain clonality.
• Serum Free Light Chain (FLC) Assay: Measures kappa and lambda free light chains; an involved-to-uninvolved ratio >=100 (with involved chain >=100 mg/L) serves as an IMWG biomarker defining active myeloma.
• Bone Marrow Aspiration and Biopsy: Core biopsy of the posterior iliac crest quantifies plasma cell percentage and architecture. Flow cytometry and fluorescence in situ hybridization (FISH) identify high-risk cytogenetic aberrations: del(17p), t(4;14), t(14;16), and 1q21 amplification.
• Targeted Osseous Biopsy: When presenting as an undiagnosed solitary lytic lesion or suspected lymphoma, image-guided percutaneous core needle biopsy is mandatory before any surgical instrumentation. Immunohistochemical staining (CD138, CD20, CD45, kappa/lambda in situ hybridization) establishes the definitive diagnosis.

7. Classification

Validated clinical and radiographic classification systems guide diagnostic differentiation, systemic staging, and orthopaedic risk stratification for pathologic fracture prevention.

International Myeloma Working Group (IMWG) Diagnostic Criteria

Mirels Scoring System for Impending Pathologic Fractures

The Mirels scoring system provides objective, validated risk stratification for long bone lesions in malignant and hematologic disease, determining the threshold for prophylactic surgical stabilization.

Score Interpretation and Fracture Risk: Total scores range from 4 to 12. A score of <=7 confers a 4% risk of fracture, indicating that radiotherapy and observation are safe. A score of 8 carries a 15% fracture risk (borderline clinical judgment). A score of >=9 confers a 33% to 100% risk of pathologic fracture, establishing a definitive indication for prophylactic surgical fixation prior to radiation or systemic therapy.

Revised International Staging System (R-ISS) for Multiple Myeloma

8. Treatment

Medical and Nonoperative Management

• Systemic Chemotherapy and Targeted Regimens: The cornerstone of management for multiple myeloma is multi-agent systemic therapy. Standard first-line regimens combine a monoclonal anti-CD38 antibody (daratumumab), a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory agent (lenalidomide), and dexamethasone (D-VRd), followed by autologous stem cell transplantation (ASCT) in eligible candidates. In primary bone lymphoma, standard induction consists of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
• Antiresorptive Bone-Modifying Agents: All patients with active multiple myeloma and documented bone disease must receive intravenous zoledronic acid (4 mg monthly adjusted for renal clearance) or subcutaneous denosumab (120 mg every 4 weeks). Denosumab is preferred in patients with severe renal impairment (creatinine clearance <30 mL/min). Antiresorptive therapy reduces skeletal-related events (pathologic fractures, spinal cord compression, hypercalcemia) by 25% to 40% and improves survival. Comprehensive dental examination must precede initiation to mitigate the risk of medication-related osteonecrosis of the jaw (MRONJ).
• Radiation Therapy:
  • Solitary Plasmacytoma: Curative-intent involved-field radiotherapy delivering 40 to 50 Gy in 20 to 25 fractions achieves local disease control rates exceeding 90%.
  • Multiple Myeloma: Palliative radiotherapy (8 Gy single fraction or 20 to 30 Gy in 5 to 10 fractions) is indicated for intractable bone pain, spinal cord decompression adjunct, or consolidated local control following surgical fixation.

Operative Management: Principles and Primary Techniques

The primary goals of orthopaedic surgery in hematologic malignancies are immediate relief of mechanical pain, restoration of skeletal structural integrity to permit immediate full weight-bearing, and protection of the entire osseous segment against future disease progression. Because irradiated and tumor-infiltrated bone lacks reliable osteogenic healing capacity, the surgical construct must provide immediate and permanent stability.

• Full-Length Intramedullary Nailing: The gold standard for impending or completed pathologic fractures of the femur, tibia, and humerus is closed or open locked intramedullary nailing spanning the full length of the bone. Reamed intramedullary nails act as internal load-sharing splints. Full-length instrumentation is mandatory: short nails or localized plates leave unprotected stress risers in the remaining bone, where subsequent disease progression leads to secondary peri-implant fractures.
• Polymethylmethacrylate (PMMA) Cement Augmentation: For large cavitary osteolytic defects treated with intramedullary nails or periarticular locking plates, thorough intralesional curettage followed by pressurized PMMA cement packing restores compressive mechanical stability and locks screws securely within poor host bone.
• Endoprosthetic Modular Reconstruction: In cases of extensive periarticular bone destruction (e.g., femoral head/neck collapse, proximal humerus destruction, or massive peritrochanteric lysis where internal fixation cannot achieve stable purchase), segmental resection and modular endoprosthetic replacement (e.g., modular proximal femoral replacement or hemiarthroplasty) provides immediate stability and early mobilization.
• Spinal Interventions:
  • Percutaneous Balloon Kyphoplasty / Vertebroplasty: For painful osteolytic vertebral compression fractures without posterior cortex disruption or epidural tumor impingement, balloon kyphoplasty restores anterior vertebral height, stabilizes the fracture fragment micro-motion, and provides rapid pain relief within 24 to 48 hours.
  • Posterior Decompression and Instrumented Fusion: Indicated for spinal instability (Spinal Instability Neoplastic Score [SINS] >=7), acute neurological deficit, or circumferential epidural tumor causing spinal cord compression. Long-segment pedicle screw fixation (two levels above and two levels below the affected vertebra) augmented with cement is standard.

Indications and Contraindications

• Definitive Operative Indications:
  • Acute displaced pathologic fracture of a long bone or mobile spine segment.
  • Mirels score >=9 in a long bone lesion.
  • Cortical destruction >50% of the bone diameter on axial CT imaging, or circumferential cortical involvement >30 mm.
  • Severe functional pain with weight-bearing refractory to medical therapy and analgesia.
  • Progressive neurological deficit or spinal canal compromise from epidural tumor or bony retropulsion.
• Relative and Absolute Contraindications:
  • Extremely poor medical condition with estimated life expectancy <4 to 6 weeks, where nonoperative hospice care and palliative analgesia are appropriate.
  • Active, uncontrolled systemic bacteremia or sepsis.
  • Disruption of the posterior vertebral body wall or epidural extension into the spinal canal is a contraindication to high-pressure vertebral cement augmentation (balloon kyphoplasty) due to the risk of spinal cord cement embolization.

9. Outcome

Prophylactic fixation of impending pathologic fractures demonstrates markedly superior outcomes compared to surgery performed after completed fracture disruption. Prophylactic intramedullary stabilization is associated with lower intraoperative blood loss (average 250 mL vs 650 mL), shorter operative times, lower wound complication rates (3% vs 11%), and significantly faster functional recovery.

Following rigid intramedullary stabilization or modular endoprosthetic reconstruction, over 85% to 92% of patients with lower extremity lesions regain independent or assisted household ambulation within 2 to 4 weeks postoperatively. Subjective pain scores drop significantly, with over 90% of patients experiencing immediate relief of mechanical fracture pain and reduced reliance on opioid analgesia. Implant survivorship for full-length intramedullary constructs exceeds 95% at 5 years, outlasting the patient’s disease-specific life expectancy in the majority of cases.

For vertebral lesions, percutaneous balloon kyphoplasty delivers rapid, durable improvements in patient-reported outcome measures, including the Roland-Morris Disability Questionnaire (RMDQ) and visual analog scale (VAS) pain scores. In randomized trials, kyphoplasty demonstrated immediate pain reduction within 1 week that was maintained through 12 months, accompanied by marked reductions in bed rest days and analgesic requirements.

10. Complications

Complications in patients undergoing orthopaedic procedures for hematologic malignancies are categorized by chronological onset, reflecting the systemic vulnerability and poor bone quality of this patient cohort.

11. Pearls and Pitfalls

• The Full-Length Instrumentation Rule: Always span the entire length of the bone when instrumenting long bone lesions in multiple myeloma. Never place a short nail or localized plate for a proximal or diaphyseal lesion; the remaining unprotected bone is prone to progressive osteolytic destruction, leading to catastrophic secondary fractures at the implant tip.
• Biopsy Before Reaming: In any patient presenting with an isolated osteolytic bone lesion without an established tissue diagnosis of multiple myeloma or lymphoma, perform an image-guided or open core biopsy first. Never ream an undifferentiated solitary bone lesion; reaming an unexpected primary osteosarcoma or chondrosarcoma contaminates the entire medullary canal and eliminates limb-salvage options.
• Constructs Must Be Permanent: Always plan surgical fixation on the assumption that biologic fracture healing will never occur. Radiotherapy and myeloma-induced Wnt pathway suppression prevent bone union. Do not rely on dynamic compression plates or minimal screw purchase; use cement-augmented screw fixation or long load-sharing intramedullary nails.
• Assess Posterior Cortical Integrity: Before performing percutaneous balloon kyphoplasty or vertebroplasty, carefully review axial and sagittal CT views. If the posterior vertebral body cortex is disrupted or epidural tumor extension is present, percutaneous cement augmentation carries a severe risk of cement extrusion into the spinal canal and neurologic injury.
• Coordinate with Medical Oncology: Coordinate surgical timing with the multidisciplinary hematology-oncology team. Avoid elective surgery during the nadir of chemotherapy-induced neutropenia and thrombocytopenia (platelet count <50,000/uL, absolute neutrophil count <1,000/uL).

12. Controversy

• Management of Mirels Score 8 Lesions: Lesions scoring 8 points represent a clinical gray zone with a 15% risk of fracture. While some clinicians advocate for immediate prophylactic intramedullary stabilization to ensure uninterrupted oncologic therapy, others recommend primary radiotherapy combined with protected weight-bearing and close bi-weekly radiographic surveillance, reserving surgery for failure of local pain relief or radiographic lesion progression.
• Denosumab vs Zoledronic Acid and Rebound Vertebral Fractures: While denosumab is superior to zoledronic acid in patients with renal impairment and demonstrates non-inferiority in delaying skeletal-related events, abrupt cessation of denosumab triggers a rebound surge in osteoclast activity and bone turnover markers. This rebound phenomenon has been linked to a cascade of multiple spontaneous vertebral compression fractures, sparking debate over mandatory consolidation with bisphosphonates upon denosumab discontinuation.
• Vertebral Augmentation in Asymptomatic or Mildly Symptomatic Fractures: The threshold for balloon kyphoplasty remains controversial. While randomized trials (such as the CAFE trial) demonstrate superior rapid pain relief and functional restoration in acute painful fractures, the routine prophylactic cement augmentation of minimally symptomatic compression fractures remains contentious due to the debated risk of adjacent-level fracture acceleration.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010. doi:10.1016/S0140-6736(10)62051-X [Level I (Therapeutic): Multicentre Randomized Controlled Trial (MRC Myeloma IX)]
• Berenson J, Pflugmacher R, Jarzem P et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011. doi:10.1016/S1470-2045(11)70008-0 [Level I (Therapeutic): Multicentre Randomized Controlled Trial (CAFE Trial)]
• Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014. doi:10.1016/S1470-2045(14)70442-5 [Level V (Expert Consensus / Diagnostic Guidelines): International Consensus Statement & Diagnostic Guidelines]
• Mirels H. Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res. 2003. doi:10.1097/01.blo.0000093045.56370.dd [Level IV (Prognostic / Diagnostic Validation): Retrospective Landmark Validation / Decision Analysis]
• Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer. 2006. doi:10.1002/cncr.21930 [Level IV (Prognostic Cohort Study): Retrospective Clinical Cohort Study]

15. Master Class Pro-Tip

In hematologic malignancies involving long bones, the operative strategy must treat the bone as mechanically compromised throughout its entire anatomical length. Never place a short intramedullary nail or localized plate that leaves unprotected cortical stress risers; systemic therapy and radiation suppress osteogenesis, meaning bone union cannot be relied upon. The construct itself must provide lifelong structural competence through full-length intramedullary load sharing, complemented by pressurized PMMA cement augmentation for substantial cortical deficits. Furthermore, in patients presenting with an isolated osteolytic lesion without a confirmed oncologic diagnosis, preoperative biopsy or intraoperative frozen section is non-negotiable to avoid catastrophic medullary contamination of a primary sarcoma.

Master Class Surgical Pearl: Surgical Stabilization in Hematologic Malignancies